RecruitingPHASE1, PHASE2NCT01799538

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator
Joel Moss, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Intervention
albuterol inhaler(drug)
Enrollment
100 enrolled
Eligibility
18-100 years · FEMALE
Timeline
20132027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01799538 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials